Realm Thera. Share Discussion Threads

[cjohn] 11/2/2021 17:26

So first release of data from the Epi-7386 Phase 1 trial.

This confirms the pre-clinical safety data: that the drug is of very low toxicity and can therefore be given in a high dose.

In a much lower dose - 200mg - the initial data published today shows that the drug has had notable positive effects.

We're now awaiting the release of data for the 400mg and 600mg samples.

[cjohn] 16/9/2020 19:06

FDA gives Fast-Track Designation to Epi-7386, Essa's lead molecule for treating castrate-resistant prostate cancer.

So development will be significantly faster and cheaper - less bureaucratically onerous.

The FDA must have been impressed by the pre-clinical data they've seen and, of course, Epi-7386 would meet a major unmet need, IF it proves to be effective.

[cjohn] 07/10/2019 09:52

I wonder if any past holders of RLM now hold Essa Pharma shares?


I read through various ESSA (EPIX) documents - research pathways etc - and also got myself as informed as I could about therapeutic approaches to prostate cancer.


And decided to hold on to the ESSA shares. As far as I can tell, there's a really promising pipeline of molecules, apart from the current lead drug.


Currently, up 100% on my implied ESSA buy price; and the share price doesn't look exorbitant given the potential upside.

[cjohn] 25/7/2019 08:58

Essa takeover still not finalised.

[zoolook] 09/4/2019 10:38

Is this broadly neutral? in that it only adds an extra urgency to make a statement of strategic intent before a delisting is forced - hopefully that it is to be acquired or wound down returning money to shareholders rather than rushing into making an acquisition.

[eezymunny] 08/4/2019 12:49

A fair chance it'll tank today I guess...

uk.advfn.com/stock-market/NASDAQ/RLM/share-news/Realm-Therapeutics-Announces-Receipt-of-Nasdaq-Lis/79643697

[zoolook] 08/4/2019 12:21

Surprised there has been no comment with the c.25% gain for those who stuck with the conversion

[papy02] 07/3/2019 12:11

Enewman36, the conversion is 25 shares for 1 ADS.

The shareprice doesn’t come into it (other than presenting a buying opportunity if you believe the value will eventually out).

[enewman36] 07/3/2019 11:58

And to add to this surely as more and more people sell as the end date looms the share price will continue to drift this giving you even less value on the conversion right?

[enewman36] 07/3/2019 11:56

Ok, so I get the process but what is the value to existing holders in going ahead with the conversion as the so called true value of the company (if indeed it is approx 17p) will still not be met surely? This is the bit I am not sure about.

[papy02] 04/3/2019 16:34

Thank you Eezymunny.

[eezymunny] 04/3/2019 16:22

HL say...

"What is happening?

The Board of Realm Therapeutics plc has announced proposals to cancel the Company’s Ordinary Shares from trading on AIM (The Alternative Investment Market). It is expected that the Company’s Shares will be delisted with effect from the close of business on 26 March 2019. However, the Company is offering the option of converting the Ordinary Shares into American Depositary Shares (ADSs) prior to the Delisting, thereby continuing to offer a trading platform for your holding. One ADS represents 25 Ordinary Shares and will trade on the NASDAQ Stock Market in the US.

What is an ADS?

ADSs are a form of stock traded in the US that represent a number of Shares in a foreign Company. The ADSs are created by a Depositary, in this instance Citibank NA.

Do I need to take any action?

For the Delisting to become effective, it must be approved at a General Meeting to be held on 15 March 2019. If you would like to submit a vote for or against the resolution to delist the Shares, please provide us with your voting instruction by noon Tuesday 12 March 2019 by clicking on your Stocks & Shares ISA in the ‘My Accounts’ section of our website. Please then select the dark blue Corporate Actions Icon alongside your Realm Therapeutics plc Shares and follow the online instructions provided. Alternatively you can give an instruction over the telephone on 0117 900 9000, subject to confirmation of your security details.

You also have 3 options to consider for your holding in Realm Therapeutics, should the Delisting be approved:


Option 1 – DEFAULT – Do nothing and receive ADSs. If you continue to hold your Shares at close of business on 15 March 2019 and the delisting is approved we will automatically arrange for them to be converted into ADSs, unless you notify us otherwise. This is to ensure you can still trade your investment and do not have to pay the 1.5% stamp duty and a US$0.05 per ADS conversion fee that would be levied on any conversion instructions we process after this date. You will receive 1 ADS in place of every 25 Shares held, with any fractional entitlement to ADSs being paid to you as cash.


Option 2 – Request to maintain your Ordinary Shares and not convert to ADSs. If you do not sell your holding before 15 March 2019, but do not wish for us to automatically convert them into ADSs, you must inform us of this before 4.30pm on Friday 15 March 2019. Please note that if the delisting proceeds there will be no market in which you can trade Shares and you would therefore find it extremely difficult to realise the value of your holding. Following the delisting any future conversion of Shares into ADSs would be a lengthy process and incur 1.5% stamp duty and a US$0.05 per ADS conversion fee. To give an instruction to not convert your Shares please call us on 0117 980 9912.


Option 3 – Sell your holding. If you wish to sell your holding before the proposed listing cancellation you must do so before close of business on 15 March 2019, unless you have requested us not to convert your Shares into ADSs (Option 2 above) in which case you will still have the opportunity to trade up to 26 March 2019. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these Shares please phone us on 0117 980 9800 or you can place a trade online. Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists. If you dispose of your holding before shareholder approval for the Delisting has been granted you do so at your own risk.


Please read the appendix of this message in order to obtain further information regarding the Delisting and Conversion to ADSs to help make your decision.


Important information for holders of Realm Therapeutics Shares within a Stocks & Shares ISA


Please note under HMRC rules unlisted Shares are not eligible to be held within a Stocks & Shares ISA. As a result, if the delisting becomes effective, any holding of Realm Therapeutics plc Shares within a Stocks & Shares ISA will need to be removed within 30 days of the effective date of the delisting (by 26 April 2019). Additionally, as the underlying Ordinary Shares will not be listed the ADSs will also be a ineligible to be held within a Stocks & Shares ISA and as such would need to be removed from your ISA by 26 April 2019.


Other information and warnings


Should you have any queries relating to the delisting please contact us on 0117 900 9000. Please note, we can provide factual assistance but cannot provide advice about which option you should choose. We hope you are satisfied with our service. If you would like to set up new products, or transfer other assets you hold to Hargreaves Lansdown please go to www.hl.co.uk or call our Investment Helpdesk on 0117 900 9000.



Yours sincerely



Charlie Balmer

Charlie Balmer

Corporate Actions



APPENDIX

QUESTIONS AND ANSWERS



Why is this happening?



“The Directors have undertaken a review of the advantages and disadvantages associated with the continued admission of the Ordinary Shares to trading on AIM, considering both access to the relevant equity capital markets and having a second public market in the Company's securities versus the cost and management time associated with maintaining a dual-quotation on AIM. Costs of the AIM listing include fees payable to the London Stock Exchange, nominated adviser and brokerage fees, shareholder communication time and costs, professional advisory fees and expenses.



“The Company also notes the costs, professional advisory fees and expenses associated with the compliance with the Takeover Code in the context of the Formal Sale Process, and reiterates the confirmation of the Takeover Panel that, subject to the AIM Delisting becoming effective, the Takeover Code will no longer apply to the Company on the basis that the Company's place of central management and control is outside of the UK, Channel Islands and the Isle of Man.



“The Board notes that approximately 40% of Ordinary Shares are, as at the date of this document, held in the form of ADSs. The Board believes the Company does not merit the ongoing costs and regulatory complexities associated with a dual listing and that it would be advantageous for all Shareholders to seek, to the extent possible, to combine trading volumes of the Ordinary Shares on AIM and the ADSs on the Nasdaq Capital Market onto a single trading exchange (Nasdaq Capital Market, wherein trades will be made in the form of ADSs). (Source: Shareholder Notice - February 2019)



When will I receive the ADSs?



If your holding is converted into ADSs at this opportunity they will be credited to your portfolio on receipt, expected to be around 28 March 2019.



Will I be able to trade the new ADSs?



Realm Therapeutics ADSs are listed and traded on NASDAQ under the ticker ‘RLM’. Once exchanged from Ordinary Shares, they will be tradeable over the telephone or by post only.



Please note that trades will be placed in US Dollars and converted to Sterling on receipt by Hargeaves Lansdown, subject to the prevailing exchange rate at that time and our standard currency conversion fees.



Furthermore, if you choose to convert to ADSs please note that you will not have any voting rights.



Additional charges may be applied by the Depositary to ADS holders for Dividends and Corporate Actions, in some instances these charges may be passed on to you from Hargreaves Lansdown. You can find more information on our overseas Share dealing service at

[papy02] 04/3/2019 14:10

Zoolook
Will HL support the process to convert AIM shares to ADSs?
Thanks

[zoolook] 04/3/2019 13:26

If you try to buy on HL a pop up warns they are about to be delisted. Can imagine it makes people think twice

[eezymunny] 27/2/2019 23:19

Slowly rising towards cash/share value (17-20p post sale?).

Mr Market has perhaps been rather thick and slow here....

[purple11] 27/2/2019 12:23

break 10 and blue sky beckons

[barnetpeter] 27/2/2019 08:52

Yes this thread is the one to use....with charts

[boystown] 22/2/2019 09:05

Do the ADSs remain listed on Nasdaq after de-listing on AIM? Can anyone clarify the implications of this /what it will mean in practice for UK holders? Cos the current valuation seems just too good to be true?

[cjohn] 21/2/2019 15:40

I think one factor putting off new investors is the complication of the conversion of ordinary shares into ADSs.

[cjohn] 21/2/2019 15:39

I'm still happy to buy below the mid!

[enewman36] 19/2/2019 12:24

Bet your not saying that today :-(

[cjohn] 19/2/2019 08:23

I was very happy to buy below the mid!